Healthcare investors: who actually funds biotech and health tech
A fund backing a therapeutics company is underwriting a decade, a clinical trial and a regulatory decision it cannot influence. A fund backing care-delivery software is underwriting a sales cycle into a hospital system. Both call themselves healthcare investors, they rarely compete for the same deal, and the gap between them is the single most useful thing to understand before you build a list.
Reviewed 2025
The state of healthcare investment
These two numbers point in opposite directions and that is the story of the sector right now. Biotech took $16.6bn in the US in 2025, just over 8% of startup investment, against a historical norm above 15% and around 20% in 2020. Meanwhile AI-powered health tech passed its entire prior-year total by November. Capital has not left healthcare so much as moved within it, away from long clinical timelines and towards software with a nearer payback.
The four kinds of healthcare investor
This is the table worth keeping. A fund tagged "healthcare" sits in one of four columns, and the columns underwrite fundamentally different risks over fundamentally different timescales. Work out which one you are in before you build a list.
| Therapeutics & drug discovery | Devices & diagnostics | Digital health & care delivery | Payer & provider software | |
|---|---|---|---|---|
| Typical entry stage | Seed, often company-formed by the fund itself | Seed to Series A | Pre-seed to Series A | Seed to Series A |
| Cheque shape | Large, tranched against milestones | Venture, with a capital plan for manufacturing | Ordinary venture | Ordinary venture |
| Wants to see | Target validation and a credible path through the clinic | A regulatory pathway and reimbursement logic | Retention, and a payer or employer willing to buy | Signed health-system contracts and a real integration |
| Time to revenue | 8-12 years, or an exit before any | 3-6 years | 12-24 months | 12-24 months |
| Biggest risk they underwrite | The trial reads out badly | Clearance slips, or nobody pays for it | Engagement decays and the payer does not renew | A procurement cycle that outlasts the runway |
| Who else must be in the round | A pharma strategic, eventually | Strategics with a distribution channel | A health system or payer as a design partner | Nobody in particular |
Healthcare investors, grouped by the cheque they write
Healthcare investors we hold in the Causo catalogue, grouped by the cheque they actually write. Open any of them to see the partners, the stage and the recent deals. This is not every healthcare investor in the market, and no catalogue is.
Life sciences specialists
Firms whose entire mandate is therapeutics, biotech and medicine.
Digital health at seed
Firms writing the first institutional cheque into care delivery and health software.
Series A and later
Firms that lead once there is clinical data, a cleared device or a signed health system.
Corporate and strategic
Pharma, payer and provider balance sheets, whose parent is also a plausible acquirer or channel.
What healthcare investors need to see
The gates that are specific to this sector, and that a generalist fundraising guide will not tell you about.
- Say which column you are in, immediatelyA digital health company pitching a therapeutics fund is asking for a cheque that firm does not write. The reverse is worse, because a software investor will not fund a trial. Name the category in the first two lines and you will get better meetings and fewer of them.
- Answer the reimbursement question before it is askedFor anything that touches care, the first serious question is who pays and under what code. A product with clinical merit and no reimbursement path is a research project. Knowing the billing route, or having a credible employer or cash-pay wedge, separates fundable from interesting.
- Bring evidence, not enthusiasmClinical claims are held to a different standard than product claims. A pilot with a named health system, a peer-reviewed result, or a cleared predicate device is worth more than any projection, and overstating evidence is the fastest way to lose a healthcare investor permanently.
- Be precise about regulatory statusThere is a large difference between exempt, 510(k), De Novo and PMA, and between a wellness claim and a medical one. Investors in this sector know it exactly. State where you are, what you have filed and what your regulatory counsel has told you.
- Model the sales cycle honestlyHealth systems and payers buy slowly, with committees and pilots that do not convert. If your plan assumes a six-month enterprise cycle into a hospital, an experienced investor will discount it on sight. Show that your runway survives the real cycle.
- Check they are still deploying in your sub-sectorBiotech’s share of US funding fell to a record low in 2025 while AI-enabled health tech grew. Several funds have quietly moved along that gradient. Recent announcements tell you which side of it a firm is on now; the website does not.
Where a healthcare investor’s real track record is published
- ClinicalTrials.gov registrations and sponsors
- FDA 510(k), De Novo and PMA clearance databases
- NIH RePORTER and SBIR grant awards
- EMA and MHRA authorisation records
- Patent filings
- Funding announcements
- Fund portfolio pages
- Partner essays, podcasts and conference talks
- Why trial and clearance records matter more here than elsewhereA therapeutics or device company leaves a dated public trail years before a portfolio page mentions it. Trial registrations and clearance filings name the sponsor, the indication and the timing, which shows who was in a category early and which investors were already alongside them.
Reading one healthcare investor’s actual record
One worked example of what reading those sources produces, from the Causo catalogue with the identity removed.
A healthcare-only vehicle sitting inside a larger venture-studio platform, which both builds companies and invests in them. The stated filter is commercially validated healthcare businesses rather than early science, and the mandate runs seed through Series A with a published cheque band of $500k to $1m.
Questions founders ask about healthcare investors
Who are the main healthcare investors?
Life sciences specialists include OrbiMed, RA Capital, Atlas Venture, ARCH Venture Partners, Versant Ventures, Third Rock Ventures, 5AM Ventures and Sofinnova Partners. On the digital health side, Flare Capital Partners, Rock Health Capital and a16z Bio + Health are active. Corporate arms including Novartis Venture Fund, Pfizer Ventures, Takeda Ventures and CVS Health Ventures invest strategically. Which of them is relevant depends far more on your sub-sector than on cheque size.
How much venture funding does healthcare get?
Less than it used to, and unevenly. US biotech took $16.6bn in 2025, just over 8% of all US startup investment, which is the lowest share in Crunchbase’s recorded history against a norm above 15%. At the same time AI-powered health tech drew $10.7bn, already 24% more than the whole of 2024. The sector total understates how differently its halves are performing.
Is biotech funding recovering?
Not on the numbers for 2025. Seed and early-stage US biotech raised $8.2bn, on track for the lowest total in years, and biotech IPOs were heading for their lowest count in years with 18 debuts. Capital that used to go into long clinical timelines has been moving towards AI and software with a nearer payback.
Do healthcare investors fund pre-clinical companies?
Therapeutics specialists do, and it is much of what they exist for. Many will company-form around science out of a university lab and fund it through the clinic in tranches tied to milestones. Digital health and provider-software investors generally will not, because their model assumes revenue within a couple of years.
What do healthcare investors look for at seed?
For therapeutics, validated target biology and a credible route through the clinic with realistic capital planning. For devices, a clear regulatory pathway and a reimbursement code. For digital health, retention data and a payer, employer or health system willing to pay rather than pilot. In all three, precision about evidence matters more than ambition.
How do I know whether a fund is genuinely active in my sub-sector?
Look at the last eighteen months of announcements rather than the website. The gap between biotech and health software widened sharply in 2025, and several generalist funds moved along it without updating their stated thesis. Recent deals, new fund closes and what partners write about are the reliable signals.